… , erlotinib plus bevacizumab and gefitinib plus pemetrexed-based chemotherapy). Asian
patients with L858R mutation had no significant OS benefits from all these treatments. …

… gefitinib in real-world patients in Asia. Importantly, the efficacy and safety of afatinib is seen
in groups of Asian patients … brain metastases, and frail patients or those with other underlying …

… In addition, erlotinib and gefitinib were grouped in … Asian patients with 19del had no OS
benefits with all approved EGFR-TKIs and combination treatment, albeit significant PFS benefits. …

… monotherapy in East Asian patients with locally advanced or … gefitinib maintenance therapy
versus gefitinib mono-therapy in East Asian patients with locally advanced or metastatic non…

… furmonertinib was superior to gefitinib in terms of progression-free survival as first-line
treatment for Chinese patients with EGFR mutation-positive NSCLC. This benefit was consistent in …

… In 2010, gefitinib (Gef) was examined as the first-line treatment for locally … in this review to
be the best treatment for all patients in the Asian population with locally advanced or metastatic …

… In this systematic review, we will compare the use of gefitinib … therapies, such as
gefitinib/lapatinib and gefitinib/pemetrexed … review and network meta-analysis revealed that Asian …

… Of all included patients, 6458 (48.3 %) were female and 5429 (40.7 %) were non-Asian. The
… , and erlotinib and gefitinib for ALT elevation; but more toxic than gefitinib for neutropenia. …

… For older patients with EGFR-mutant advanced NSCLC, EGFR … Survival benefit of
chemotherapy after failure of gefitinib … for older patients with EGFR-mutant advanced NSCLC who …

… A recent phase III, randomized, controlled trial 8 , (LUX-Lung 7), revealed that afatinib
exerted significant benefits in PFS compared to gefitinib in NSCLC patients with EGFR-activating …